Zhang Wei-Jun, Shi Hou-Zhen, Guo Mei-Na, Xu Long-Fei, Zhai Hong-Ru, Liu Zi-Zhong, Zhu Yong-Qiang, Zhang Wei-Ning, Wang Jia
The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.
Front Mol Neurosci. 2023 Sep 25;16:1149906. doi: 10.3389/fnmol.2023.1149906. eCollection 2023.
Peroxisome proliferator-activated receptor PPARγ coactivator-α (PGC-1α) is concentrated in inhibitory interneurons and plays a vital role in neuropsychiatric diseases. We previously reported some characteristic features of schizophrenia (SZ) in GABAergic neuron-specific knockout (KO) mice (Dlx5/6-Cre: -1). However, there is a fundamental gap in the molecular mechanism by which the gene is involved in the neurobehavioral abnormalities of SZ. The loss of critical period (CP) triggers-maturations of parvalbumin interneurons (PVIs) and brakes-and the formation of perineuronal nets (PNNs) implicates mistimed trajectories during adult brain development. In this study, using the KO mouse line, we investigated the association of gene deletion with SZ-like behavioral deficits, PVI maturation, PNN integrity and synaptic ultrastructure. These findings suggest that gene deletion resulted in a failure of CP onset and closure, thereby prolonging cortical plasticity timing. To determine whether the manipulation of the PNN structure is a potential method of altering neuronal plasticity, GM6001, a broad-spectrum matrix metalloproteinase (MMP)-inhibitor was applied. Here we confirmed that the treatment could effectively correct the CP plasticity window and ameliorate the synaptic ultrastructure in the KO brain. Moreover, the intervention effect on neuronal plasticity was followed by the rescue of short-term habituation deficits and the mitigation of aberrant salience, which are some characteristic features of SZ. Taken collectively, these findings suggest that the role of PGC-1α in regulating cortical plasticity is mediated, at least partially, through the regulation of CP onset/closure. Strategically introduced reinforcement of molecular brakes may be a novel preventive therapy for psychiatric disorders associated with PGC-1α dysregulation.
过氧化物酶体增殖物激活受体γ共激活因子-α(PGC-1α)集中在抑制性中间神经元中,在神经精神疾病中起至关重要的作用。我们之前报道了γ-氨基丁酸能神经元特异性敲除(KO)小鼠(Dlx5/6-Cre: -1)中精神分裂症(SZ)的一些特征。然而,该基因参与SZ神经行为异常的分子机制存在根本差距。关键期(CP)的缺失触发小白蛋白中间神经元(PVIs)的成熟并制动,而神经元周围网络(PNNs)的形成暗示成年大脑发育过程中的时机错误轨迹。在本研究中,我们使用KO小鼠品系,研究了基因缺失与SZ样行为缺陷、PVI成熟、PNN完整性和突触超微结构之间的关联。这些发现表明,基因缺失导致CP起始和关闭失败,从而延长了皮质可塑性时间。为了确定操纵PNN结构是否是改变神经元可塑性的潜在方法,应用了GM6001,一种广谱基质金属蛋白酶(MMP)抑制剂。在这里,我们证实该治疗可以有效纠正KO大脑中的CP可塑性窗口并改善突触超微结构。此外,对神经元可塑性的干预作用伴随着短期习惯化缺陷的挽救和异常显著性的减轻,这些都是SZ的一些特征。综上所述,这些发现表明PGC-1α在调节皮质可塑性中的作用至少部分是通过调节CP起始/关闭来介导的。策略性地引入分子制动的增强可能是一种针对与PGC-1α失调相关的精神疾病的新型预防疗法。